Resumen de: WO2023091873A1

Small molecule inhibitors of the localization of lipoprotein CDE (LolCDE) complex that is found in the membrane of bacteria. Searches for suitable candidates for the LolCDE complex led to the discovery of an inhibitor named lolamycin. Lolamycin specifically targets Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and is selective over Gram-negative and Gram-positive commensal bacteria, thereby avoiding perturbation of the gut microbiome.

Resumen de: US2023158133A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding Wilms' Tumor Protein (WT1), for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1, CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding WT1 for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1, CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.

Resumen de: WO2023086942A2

Disclosed herein are methods and kits for quantifying the presence of a microorganism in a sample. Specifically, disclosed are methods for quantifying a pathogen in a sample, such as a food sample, to determine if the levels of pathogen present in the sample are within an acceptable range.

Resumen de: US2023149524A1

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Resumen de: WO2022013143A1

The invention relates to a genetically modified microorganism for making an oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.

Resumen de: WO2023080703A1

The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously used as a prophylactic or therapeutic composition that is configured to administer a bacterium and an immune checkpoint inhibitor in combination into cancer, especially, a type of resistant cancer difficult to treat with a single anticancer therapy, to remarkably inhibit the size of a tumor, thereby improving the survival rate.

Resumen de: WO2022036159A2

Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor- resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. Also provided are immunostimulatory bacteria for use as vaccines, and for delivery of mRNA. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and to tumors and permits, among other routes, systemic administration of the immunostimulatory bacteria. The increase in colonization of phagocytic cells also provides for use of immunostimulatory bacteria for direct tissue administration for use as vaccines.

Resumen de: US2023146032A1

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

Resumen de: US2023141226A1

An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.

Resumen de: WO2023080703A1

The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously used as a prophylactic or therapeutic composition that is configured to administer a bacterium and an immune checkpoint inhibitor in combination into cancer, especially, a type of resistant cancer difficult to treat with a single anticancer therapy, to remarkably inhibit the size of a tumor, thereby improving the survival rate.

Resumen de: WO2021198376A1

The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/ or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.

Resumen de: CN116083275A

本发明公开了一种印第安纳沙门菌及其应用，属于微生物技术领域。本发明的沙门菌为印第安纳沙门菌(Salmonella enterica subsp.enterica serovar Indiana)Sal29‑51，已于2022年7月15日保藏于广东省微生物菌种保藏中心(GDMCC)，保藏地址：中国广州市先烈中路100号大院59号楼5楼，保藏号：GDMCC No：62623。本发明的印第安纳沙门菌Sal29‑51携带多种耐药基因，对多种传统药物表现出耐药性，对目前临床治疗沙门菌感染的一线药物也表现出高水平耐药，对多粘菌素B不敏感，可作为筛选功能微生物/新型抗菌药物的模型材料，具有良好的应用前景。

Resumen de: WO2023073640A1

An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.

Resumen de: US2023140113A1

The present invention discloses a highly efficient method for detecting opioids, opiates, cannabinoids, or benzodiazepines present in a sample, comprising the steps of adding to said sample an enzyme with β-glucuronidase activity originated from genus Brachyspira or any mutant derived thereof; incubating the sample with the enzyme; and detecting said opioids, opiates, cannabinoids, or benzodiazepines by means of a suitable technique.

Resumen de: US2023136602A1

Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

Resumen de: US2023137821A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Resumen de: US2023137914A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Resumen de: US2023138583A1

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Resumen de: US2023137174A1

The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.

Resumen de: WO2021263105A1

The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.

Resumen de: GB2612409A

Provided in the present invention are an InDel molecular marker of ultrasonic mutagenesis salmonella typhimurium hisD gene and the use thereof, which belong to the field of molecular biology. In the present invention, it is found by means of ultrasonically inducing salmonella typhimurium and sequencing same that all InDel mutations occur in a core mutation region of the hisD gene. Therefore, the core mutation region is used as the InDel molecular marker and is used for analyzing the determination of an insertion or deletion type of a gene reverse mutation. Moreover, the InDel molecular marker also can be used to analyze the relationship between the hisD gene sequence and the function of a protein encoded thereby.

Resumen de: EP3929300A1

Disclosed are genetically-engineered gram-negative bacterial cells for the production of an oligosaccharide of interest, wherein the bacterial cell possesses a saccharide transporter and/or a porin being expressed from a recombinant gene or a deregulated endogenous gene, thereby facilitating the translocation of the oligosaccharide of interest from the cell's cytoplasm into the cell's environment. Also disclosed are methods for producing an oligosaccharide of interest which used said genetically-engineered gram-negative bacterial cells.

Resumen de: KR20230059355A

본 발명은 waaJ 유전자 및 spiC 유전자 중 적어도 하나가 결실된 살모넬라 변이균주의 제조 방법 및 이를 함유하는 살모넬라 생백신 조성물에 관한 것이다. 본 발명에 따른 살모넬라 변이균주의 제조 방법은 살모넬라 갈리나리움(S gallinarium)의 염색체에서 waaJ 또는 spiC 유전자의 5'- 및 3'-말단에 연결되어 있는 DNA 단편을 각각 증폭시키는 단계, waaJ 또는 spiC 유전자의 5'- 및 3'-말단에 연결된 DNA 단편을 라이게이션시키고, 자살벡터(suicide vector)에 삽입하여, waaJ 또는 spiC 유전자의 5'-말단에 연결되는 DNA 단편과 3'-말단에 연결되는 DNA 단편이 결합된 DNA를 함유하는 자살벡터를 제조하는 단계 및 waaJ 또는 spiC 유전자의 5'-말단에 연결되는 DNA 단편과 3'-말단에 연결되는 DNA 단편이 결합된 DNA를 함유하는 자살벡터를 살모넬라 속 균주의 염색체 DNA에 접합시킨 다음, waaJ 또는 spiC 유전자가 결실된 살모넬라 변이균주를 선별하는 단계를 포함한다.

Resumen de: US2023131960A1

The present invention relates to the treatment of diseases induced by Enterobacteriae. The inventors evaluated, in a multicellular in vitro model associating cells representing human enterocytes (Caco-2 cells), goblet mucus secreting cells (HT29-MTX) and M cells, whether Bacteroides fragilis, a non-enterotoxigenic strain, could be useful to limit the severity of the Salmonella Heidelberg infection, with an hypermutator phenotype, by analyzing their impact on growth and mucosal translocation. Thus, the present invention relates to a Bacteroides fragilis strain for use in the treatment of diseases induced by Enterobacteriae in a subject in need thereof.

Resumen de: WO2021255480A1

The present invention provides for a modified autotransporter and the use of genetically engineered microorganisms comprising said modified autotransporters in the treatment of infectious and neoplastic disease. The present invention therefore also relates to vaccine and immunotherapeutic compositions comprising said genetically engineered microorganism.